{"id":"W3028216699","doi":"10.1002/oby.22794","title":"Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5","year":2020,"lang":"en","type":"article","venue":"Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":true,"ca_institutions":"York University","funders":"NIHR Leicester Biomedical Research Centre; Mitsubishi Tanabe Pharma Corporation; Servier; Eisai; Zafgen; Astellas Pharma; Mylan; MannKind Corporation; Bausch Health; University of Pennsylvania; Novo Nordisk; National Institute for Health and Care Research; Intarcia Therapeutics; Teva Pharmaceutical Industries; Gilead Sciences; Sanofi; National Institute of Diabetes and Digestive and Kidney Diseases; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Semaglutide; Medicine; Waist; Placebo; Overweight; Obesity; Type 2 diabetes; Tolerability; Weight loss; Population; Circumference; Clinical trial; Physical therapy; Internal medicine; Diabetes mellitus; Adverse effect; Alternative medicine; Endocrinology; Liraglutide; Environmental health","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003840154,0.0001419786,0.0005556843,0.00002610911,0.0000732082,0.000007253214,0.0001535963,0.00003010419,0.00009701229],"category_scores_gemma":[0.000249237,0.00006874808,0.0003460063,0.0001690277,0.00003594695,0.00001661928,0.00006890726,0.00002518596,0.00001660799],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007402268,"about_ca_system_score_gemma":0.00003900145,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007099059,"about_ca_topic_score_gemma":0.000040022,"domain_scores_codex":[0.9989038,0.00007895604,0.0003978956,0.0001887882,0.0002489762,0.0001816382],"domain_scores_gemma":[0.9989242,0.0003146331,0.0001986639,0.0004021003,0.00006948297,0.00009094558],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001642673,0.005367277,0.8157032,0.0007014378,0.004283584,0.000007105579,0.003489494,0.00004390031,0.01037648,0.002804926,0.04311175,0.1124682],"study_design_scores_gemma":[0.01183867,0.005991994,0.4458647,0.0001528601,0.004891994,4.404163e-7,0.000577096,0.0004289241,0.1341103,0.000174488,0.3957636,0.0002049507],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9868397,0.0003752459,0.0004521823,0.006928496,0.0001671277,0.004030226,0.00009120491,0.00002173859,0.001094102],"genre_scores_gemma":[0.9944232,0.0001220101,0.001578374,0.0009797552,0.00014041,0.0001508599,0.0000138175,0.00001428585,0.002577354],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3698384,"threshold_uncertainty_score":0.2803465,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06482362611717103,"score_gpt":0.3124158583845207,"score_spread":0.2475922322673497,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}